Hot Investor Mandate 1: Corporate VC Invests in Repurposed Drugs and New Combinations in CNS and Respiratory Diseases

Featured Posts

• Life Science Nation’s Redefining Early Stage Investments (RESI) Conference Series Changed the Game – Here’s How.

  By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series Life Science Nation’s Redefining Early Stage Investments (RESI) conference series is unique in several ways: The Innovation Challenge that takes place at every RESI conference is a huge hit with early stage global investors seeking firms that align with their investment mandates.  […]

• Meeting Investors Through the RESI Innovation Challenge

  By Chris Cummings, Senior Marketing Manager, LSN The RESI Conference offers a unique platform for scientist-entrepreneurs to meet investors. For selected companies competing in the RESI Innovation Challenge, the platform expands exponentially. Participating in the Challenge opens a new universe of potential meeting opportunities, well beyond the 16 time slots available in Partnering. The objective […]

• Interview with Yasaman, Winner of the Innovation Challenge in RESI Toronto

  An interview with Yasaman Soudagar, Founder & CEO, Neurescence – By Greg Mannix, VP of International Business Development, LSN Interview with Yasaman Soudagar: This year’s winner of the Innovation Challenge at RESI on MaRS was Neurescence, a Toronto-based company that has combined the power of novel optical imaging technology with advanced machine learning and quantum machine […]

• Hot Investor Mandate 1: Subsidiary of Large USA and China-Based Biotech Seeks Investment and In-Licensing Opportunities in Cell & Gene Therapies, Invests Up to $10M

  An emerging company with China headquarters is focusing on the development of the best-in-class immunotherapy technology for cancer cure. Teamed up with outstanding immunologists and molecular biologists, the firm has generated a strong pipeline of Chimeric Antigen Receptor (CAR) product candidates to treat a wide variety of liquid and solid tumors. The firm is a […]

• Hot Investor Mandate 2: VC Arm of Japanese Pharma Invests in Early-Stage Therapeutics and Platform Technologies in a Wide Range of Indications, Including CNS

  A corporate venture subsidiary of a Japan pharmaceutical is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over […]